ImmuDyne Announces Q3 2016 Net Sales Up 395%, Adjusted Non-GAAP Net Income
MT. KISCO, N.Y., Nov. 15, 2016 (GLOBE NEWSWIRE) -- lmmuDyne (OTCQB:IMMD) announced today its financial results for the 3rd quarter, and year to date, for the period ended September 30, 2016.
Quarterly net sales increased 395% to $1.38 million. Year to date sales increased to $4.25 million. Adjusted non-GAAP Net (loss) income for the quarter was $(55,420), and $31,117 year to date.
Please see the schedule accompanying this release for a reconciliation of adjusted net income to the comparable GAAP measure.
lmmuDyne, Inc. (the "Company") is a health and wellness company which develops, manufactures, markets, and sells innovative lifestyle products. The Company's lead products contain its proprietary yeast beta glucans that have been shown through testing and analysis to support the immune system. The Company's products include once a day oral intake capsules as well as topical serums and creams for skin application. lmmuDyne also has developed a proprietary natural delivery technology for potential new market opportunities. All of lmmuDyne's intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com.
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release, including projections with respect to lmmuDyne's results of operations, may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.
|Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Income (Loss)|
Three Months Ended
Nine Months Ended
|Adjusted Non-GAAP Net Income:|
|GAAP Net (loss) income attributable to Immudyne, Inc.||$||(226,651||)||$||8,119||$||(488,676||)||$||(11,243||)|
|Expense for contingent options||55,591||10,500||133,324||14,500|
|Common stock issued for compensation||76,667||-||306,667||-|
|Fair value of options and warrants issued for services||32,983||-||73,812||-|
|Amortization of debt discount||5,990||-||5,990||-|
|Total non-GAAP adjustments||171,231||10,500||519,793||14,500|
|Adjusted non-GAAP Net (loss) income attributable to Immudyne, Inc.||$||(55,420||)||$||18,619||$||31,117||$||3,257|
This earnings release contains non-GAAP financial measures that may not be directly comparable to other similarly titled measures used by other companies. For purposes of Regulation G, a non-GAAP financial measure is a numerical measure of a company's historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable measure calculated and presented in accordance with GAAP in the statements of operations, balance sheets, or statements of cash flows of the Company; or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable measure so calculated and presented. Pursuant to the requirements of Regulation G, the Company has provided reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures. These non-GAAP measures are provided because management of the Company uses these financial measures in monitoring and evaluating the Company's ongoing financial results and trends. Management uses this non-GAAP information as an indicator of business performance, and evaluates overall management with respect to such indicators. These non-GAAP measures should be considered in addition to, but not as a substitute for, measures of financial performance prepared in accordance with GAAP.
Contact: ImmuDyne, Inc. Mark McLaughlin: +1-914-714-8901Source: ImmuDyne, Inc.
Released November 15, 2016